HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Prevention of chronic rejection by pravastatin in a rat kidney transplant model.

AbstractBACKGROUND:
Pravastatin when administered with cyclosporine (CsA) has been shown to ameliorate transplant vasculopathy in the clinical setting. Previously we showed that pravastatin prevents chronic rejection in rat cardiac and liver transplant models. Here we determine whether pravastatin prevents chronic rejection in a rat renal allograft model.
METHODS:
Orthotopic renal transplantations were performed using Fisher 344 rats as donors and Lewis rats as recipients. Recipients were treated with low-dose CsA for 10 days to prevent acute rejection. Recipients were divided into three groups: CsA, CsA + pravastatin, and syngeneic. Renal function was assessed by serum creatinine level at day 130. Allografts were evaluated by histology and immunohistochemistry. Serum levels of alloantibodies were measured by flow cytometry. Intragraft cytokine mRNA expression was determined by semiquantitative reverse transcriptase-polymerase chain reaction. Intragraft levels of the antiapoptotic Bag-1 gene were measured by Western blot.
RESULTS:
Unlike allografts from the pravastatin group, control allografts demonstrated glomerulosclerosis, vascular obliteration, tubular atrophy, and interstitial fibrosis. Serum creatinine levels and graft infiltration of T cells and macrophages in the pravastatin-treated animals were significantly lower. Intragraft cytokines showed a T helper 2 polarization and decreased transforming growth factor-beta in the pravastatin group. Intragraft expression of Bag-1 was increased in the pravastatin group.
CONCLUSION:
This study demonstrates the ability of pravastatin to inhibit chronic rejection in rat renal allografts. Pravastatin's pleiotropic effects of reducing intragraft inflammatory cytokines, inhibiting immune cell infiltration, and causing up-regulation of the antiapoptotic gene Bag-1 suggest that its ability to prevent transplant chronic rejection may be multifactorial.
AuthorsPing Ji, Ming-Sing Si, Yale Podnos, Helen Chow, Earl Steward, David K Imagawa
JournalTransplantation (Transplantation) Vol. 74 Issue 6 Pg. 821-7 (Sep 27 2002) ISSN: 0041-1337 [Print] United States
PMID12364863 (Publication Type: Journal Article)
Chemical References
  • BCL2-associated athanogene 1 protein
  • Carrier Proteins
  • Cytokines
  • DNA-Binding Proteins
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Immunoglobulin G
  • Immunoglobulin M
  • Isoantibodies
  • Transcription Factors
  • Pravastatin
Topics
  • Animals
  • Carrier Proteins (genetics)
  • Chronic Disease
  • Cytokines (biosynthesis, genetics)
  • DNA-Binding Proteins
  • Graft Rejection (prevention & control)
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors (therapeutic use)
  • Immunoglobulin G (blood)
  • Immunoglobulin M (blood)
  • Isoantibodies (blood)
  • Kidney (pathology, physiology)
  • Kidney Transplantation (immunology)
  • Male
  • Pravastatin (therapeutic use)
  • Rats
  • Rats, Inbred F344
  • Rats, Inbred Lew
  • Transcription Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: